14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
LEXX vs SRZN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LEXX carries a Unified Composite Score of 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin).
Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both LEXX (33.3/100 SELL) and SRZN (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Competes within the Biotechnology value chain with $602.5M market capitalization and -485.4% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ LEXX vs SRZN Key Questions & Quantitative Answers
As of Nov 16, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Lexaria Bioscience Corp. (LEXX) in the Tradestie Institutional Equity Comparison Engine, winning 7–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). LEXX carries a Unified Composite Score of 33.3/100 (SELL) at $4.41 (N/M Forward P/E, -3862.9% operating margin), whereas SRZN carries 34.3/100 (SELL) at $32.32 (N/M Forward P/E, -485.4% operating margin). Defensive Composite Rating Caution: Although SRZN compares more favorably head-to-head, both LEXX (33.3/100 SELL) and SRZN (34.3/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
SRZN leads the Growth & Scale pillar: LEXX posts -88.5% YoY revenue growth and +0.0% YoY earnings growth on $194,000 TTM revenue (100.0% gross margin, -3862.9% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LEXX cumulative revenue shifted N/A while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, LEXX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.
LEXX screens cheaper on headline valuation multiples. LEXX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 30.7x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 48.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LEXX (-162.8% ROE) versus SRZN (-62.8% ROE) capital efficiency.
In options market volatility and institutional positioning, LEXX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (11.09β · 92% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (5th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.21β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.